These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 12841924)
61. Nasal application of a gel formulation of N-acetyl-aspartyl glutamic acid (NAAGA) compared with placebo and disodium cromoglycate in the symptomatic treatment of pollinosis. Althaus MA; Pichler WJ Allergy; 1994 Mar; 49(3):184-8. PubMed ID: 7911011 [TBL] [Abstract][Full Text] [Related]
62. Efficacy and tolerability of azelastine nasal spray in the treatment of allergic rhinitis: large scale experience in community practice. Wober W; Diez Crespo C; Bähre M Curr Med Res Opin; 1997; 13(10):617-26. PubMed ID: 9327196 [TBL] [Abstract][Full Text] [Related]
63. [Therapy of chronic allergic conjunctivitis with sodium cromoglycate (lecrolin)]. Polunin GS; Makarov IA Vestn Oftalmol; 1997; 113(2):21-2. PubMed ID: 9229898 [TBL] [Abstract][Full Text] [Related]
64. Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography. De Weck AL; Derer T; Bähre M Clin Exp Allergy; 2000 Feb; 30(2):283-7. PubMed ID: 10651782 [TBL] [Abstract][Full Text] [Related]
65. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Carr WW; Ratner P; Munzel U; Murray R; Price D; Canonica GW; Mullol J; Virchow JC; Lieberman P; Meltzer E; Bachert C Allergy Asthma Proc; 2012; 33(6):450-8. PubMed ID: 23127291 [TBL] [Abstract][Full Text] [Related]
66. Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis. Ciprandi G; Catrullo A; Tosca M; Cerqueti P; Mondino C; Passalacqua G; Canonica GW J Investig Allergol Clin Immunol; 1999; 9(1):35-8. PubMed ID: 10212855 [TBL] [Abstract][Full Text] [Related]
67. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. van Bavel J; Howland WC; Amar NJ; Wheeler W; Sacks H Allergy Asthma Proc; 2009; 30(5):512-8. PubMed ID: 19747429 [TBL] [Abstract][Full Text] [Related]
68. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Crampton HJ Clin Ther; 2002 Nov; 24(11):1800-8. PubMed ID: 12501875 [TBL] [Abstract][Full Text] [Related]
69. [Clinical assessment of azelastine nasal spray in seasonal allergic rhinitis]. Arcimowicz M; Samoliński B; Zawisza E Pol Merkur Lekarski; 1998 Dec; 5(30):363-7. PubMed ID: 10101526 [TBL] [Abstract][Full Text] [Related]
70. Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis. Odelram H; Björkstén B; af Klercker T; Rimås M; Kjellman NI; Blychert LO Allergy; 1989 Aug; 44(6):432-6. PubMed ID: 2572181 [TBL] [Abstract][Full Text] [Related]
71. Sequential therapy with azelastine in seasonal allergic rhinitis. Deutsche Rhinitis Studiengruppe (German Rhinitis Study Group). Kremer B; Klimek L; Gülicher D; Degen M; Mösges R Arzneimittelforschung; 1999 Nov; 49(11):912-9. PubMed ID: 10604044 [TBL] [Abstract][Full Text] [Related]
72. Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. Pearlman DS; Grossman J; Meltzer EO Ann Allergy Asthma Immunol; 2003 Sep; 91(3):258-62. PubMed ID: 14533657 [TBL] [Abstract][Full Text] [Related]
73. Comparative therapeutic studies with Tilavist. Alexander M Allergy; 1995; 50(21 Suppl):23-9; discussion 34-8. PubMed ID: 7785747 [TBL] [Abstract][Full Text] [Related]
74. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis. Orfeo V; Vardaro A; Lena P; Mensitieri I; Tracey M; De Marco R Eur J Ophthalmol; 2002; 12(4):262-6. PubMed ID: 12219994 [TBL] [Abstract][Full Text] [Related]
75. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491 [TBL] [Abstract][Full Text] [Related]
77. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Day JH; Briscoe MP; Rafeiro E; Hewlett D; Chapman D; Kramer B Allergy Asthma Proc; 2004; 25(1):59-68. PubMed ID: 15055564 [TBL] [Abstract][Full Text] [Related]
78. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Berger WE; White MV; Ann Allergy Asthma Immunol; 2003 Aug; 91(2):205-11. PubMed ID: 12952117 [TBL] [Abstract][Full Text] [Related]
79. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. Weiler JM; Meltzer EO; Benson PM; Weiler K; Widlitz MD; Freitag J J Allergy Clin Immunol; 1994 Dec; 94(6 Pt 1):972-80. PubMed ID: 7798545 [TBL] [Abstract][Full Text] [Related]
80. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model. Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]